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The Interleukin-23 (IL-23)/IL-23R signaling axis is an important inflammatory pathway,
involved in the stimulation and regulation of the T helper (Th) 17 lymphocytes, resulting
in the production of IL-17. Aside from auto-immunity, this cytokine has also been linked to
carcinogenesis and polymorphisms in the IL-23R gene are associated with an increased
risk for the development of a number of different cancers. Activation of the IL-23 pathway
results in the up-regulation of STAT3 and it is thought that the pathological consequences
associated with this are in part due to the production of IL-17. We have previously identi-
fied IL-23A as pro-proliferative and epigenetically regulated in non-small cell lung cancer
(NSCLC).The current study aims to evaluate IL-23R in greater detail in NSCLC. We demon-
strate that IL-23R is expressed and epigenetically regulated in NSCLC through histone
post-translation modifications and CpG island methylation. In addition, Gemcitabine treat-
ment, a chemotherapy drug used in the treatment of NSCLC, resulted in the up-regulation
of the IL-23R. Furthermore, Apilimod (STA 5326), a small molecule which blocks the expres-
sion of IL-23 and IL-12, reduced the proliferative capacity of NSCLC cells, particularly in the
adenocarcinoma (A549) sub-type. Apilimod is currently undergoing investigation in a num-
ber of clinical trials for the treatment of auto-immune conditions such as Crohn’s disease
and Rheumatoid Arthritis. Our results may have implications for treating NSCLC patients
with Gemcitabine or epigenetic targeted therapies. However, Apilimod may possibly pro-
vide a new treatment avenue for NSCLC patients. Work is currently ongoing to further
delineate the IL-23/IL-23R axis in this disease.
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INTRODUCTION
Lung cancer is a worldwide health burden, with numbers increas-
ing both in terms of incidence and mortality. In 2008, there was
an estimated 1.61 million cases of lung cancer, which accounted
for 12.7% of total cancer incidence, while in Europe an estimated
410,000 cases of lung cancer occurred in 2012 (Ferlay et al., 2013).
In terms of mortality, lung cancer accounted for 18.2% of all cancer
related deaths, which is equivalent to 1.38 million people (Ferlay
et al., 2010). In Europe an estimated 353,000 deaths occurred in
2012 for lung cancer (Ferlay et al., 2013). Due to the difficulties in
early detection, combined with fact that the majority of patients
present at an advanced stage, lung cancer has a high morbidity,
5-year survival rates continue to remain poor, at approximately 6–
14% in males and 7–18% in females (Youlden et al., 2008). Recently
lung cancer has overtaken breast and prostate as the biggest cancer
killer in females and males respectively in a number of countries.
Inflammation plays an important role in lung carcinogenesis
(O’Callaghan et al., 2010), given that individuals with inflam-
matory lung conditions have an increased risk of lung cancer
development. This risk can persist even in the absence of tobacco
use, further underscoring the role of chronic inflammation in lung
carcinogenesis (Demaria et al., 2010; Mortimer et al., 2012). Due
to the massive global burden of lung cancer in both smoking and
non-smoking individuals and in particular the dramatic rise in
the disease in never smokers, there is an urgent need to identify
both new biomarkers in this disease and novel druggable targets
to improve treatment options and increase survival rates. To this
end inflammatory mediators may provide a significant innovative
therapeutic avenue in this disease (Demaria et al., 2010).
We have previously discussed the potential role of epigenetics
in the setting of lung disease (Lawless et al., 2009, 2010). Indeed
aberrant epigenetic events are frequent in cancer (You and Jones,
2012), including lung cancer (Balgkouranidou et al., 2013). Epige-
netic targeting of lung cancer continues to be actively researched
(Juergens et al., 2011; Tsai et al., 2012). Within this context we have
shown that many pro-inflammatory cytokines and genes associ-
ated with pro-inflammatory cues are epigenetically regulated and
can be targeted in lung cancer using epigenetic targeting agents
(Baird et al., 2011a,b; Cathcart et al., 2011). Most recently we have
shown that Interleukin-23 (IL-23) as being pro-proliferative and
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epigenetically regulated in non-small cell lung cancer (NSCLC)
(Baird et al., 2013).
Interleukin-23 and IL-12 are members of a small family of
pro-inflammatory hetero-dimeric cytokines and are part of the
wider IL-6 superfamily (Croxford et al.,2012;Vignali and Kuchroo,
2012). Both cytokines share a common p40 sub unit that is cova-
lently linked either to a p35 subunit to form IL-12 or to a p19 sub
unit to form IL-23 (Oppmann et al., 2000). IL-12 was considered
as the cytokine responsible for a number of auto-immune diseases
such as experimental auto-immune encephalomyelitis (EAE), an
animal model of Multiple Sclerosis. However, knockout murine
studies demonstrated that this was not the case, as p35−/− mice
were susceptible to EAE but p40−/− mice were resistant (Becher
et al., 2002). This was confirmed in p19−/− mice, where it was
shown that p19 was essential for the development of EAE (Cua
et al., 2003).
Activated Dendritic Cells (DC) and macrophages are both
sources of IL-23 (Croxford et al., 2012). When stimulated by IL-
23, macrophages produce TNF-α, IL-1, and IL-23 itself (Duvallet
et al., 2011). IL-23 promotes inflammatory responses such as in
the defense against bacterial infection, up-regulation of angiogenic
factors and MMPs (Langowski et al., 2006) and drives an IL-17 pro-
ducing T cell population (Th 17) in part through the activation
of the STAT3 pathway (Langowski et al., 2006; Harris et al., 2007).
It has been shown that IL-23 provides a connection between the
pro-inflammatory processes which promote tumor growth and
the failure of adaptive immune mediators to penetrate tumors
(Langowski et al., 2006; Langowski et al., 2007). As such targeting
IL-23 mediated Th17 responses may have important implications
in the treatment of pro-inflammatory conditions including cancer
(Miossec and Kolls, 2012).
The receptor, through which IL-23 elicits its effects, IL-23R, is
composed of an IL-12Rβ1, a subunit common to the IL-12 recep-
tor, and an IL-23R chain (Duvallet et al., 2011). Monocytes, DC,
natural killer cells, natural killer T cells, and myeloid cells, amongst
others, express IL-23R (Parham et al., 2002; Duvallet et al., 2011).
Furthermore, polymorphisms in the IL-23R have been linked to
a number of cancers, including gastric (Chen et al., 2010), col-
orectal (Poole et al., 2012), oral (Chien et al., 2012), esophageal
(Chu et al., 2012), leukemia (Qian et al., 2013a), hepatitis B virus
(HBV)-related hepatocellular carcinoma (Xu et al., 2013), breast,
lung, and nasopharyngeal cancer (Zheng et al., 2012). In IL-23R
knockout mice, the tumor growth of both B16F10 melanoma and
LL2 lung carcinoma were inhibited in the IL-23R−/− mice (Lan-
gowski et al., 2006). Expression of the IL-23R is associated with
pro-inflammatory cues as it can be regulated by various cytokines
including TNF-α (Charles et al., 2009), IL-6 (Zhou et al., 2007), IL-
21, and IL-23 itself (Ivanov et al., 2007). Elevated levels of IL-23R
receptor expression have also been demonstrated in ovarian can-
cer (Charles et al., 2009), NSCLC (Li et al., 2013) and in colorectal
cancer (Lan et al., 2011; Suzuki et al., 2012).
As such, the IL-23/IL-23R axis is emerging as an impor-
tant potential therapeutic pathway in both auto-immune con-
ditions and the carcinogenic process. Following from this, a
small molecule inhibitor has been developed called Apilimod
mesylate (STA 5326) that selectively inhibits the production
of the cytokines, IL-12 and IL-23 (Wada et al., 2007), and is
currently undergoing evaluation in a number of clinical trials in
auto-immune conditions (Billich, 2007; Wada et al., 2012).
We and others have previously identified IL-23 as pro-
proliferative (Baird et al., 2013; Li et al., 2013), and epigenetically
regulated in NSCLC (Baird et al., 2013). In this study we there-
fore sought to examine the role of IL-23R in NSCLC in greater
detail, and to determine the effects of Apilimod on NSCLC cells.
We show that similar to what we have previously observed for
IL-23A, expression of IL-23R is also epigenetically regulated, and
affected by chemotherapeutic agents. We also show that targeting
IL-12/IL-23 production using Apilimod results in significant anti-
proliferative responses in NSCLC cell lines, further underlining
the therapeutic potential of targeting this pathway in cancer.
MATERIALS AND METHODS
CELL LINES
The A549 (adenocarcinoma) and SK-MES-1 (squamous cell car-
cinoma) were purchased from the ATCC (LGC Promochem, Ted-
dington, UK). All cell culture reagents were purchased from Lonza
(Walkersville, MD, USA) unless stated otherwise. Cells were main-
tained at 37°C in a humidified atmosphere containing 5% CO2 in
the following media; A549 – F-12 (Ham) medium supplemented
with 10% (v/v) FBS, penicillin streptomycin (500 U/mL), and
2 mM l-glutamine. SK-MES-1 – EMEM with the addition of 10%
(v/v) FBS,penicillin streptomycin (500 U/mL),2 mM l-glutamine,
and 0.1 M non-essential amino acids.
PRIMARY TUMOR SAMPLES
A series of 37 tumor specimens (21 adenocarcinoma, 16 squa-
mous cell carcinoma) were taken from patients presenting with
early stage NSCLC at either St. James’s Hospital, Dublin, Ireland
or were obtained from the Leicester Royal Infirmary lung can-
cer biobank, Leicester, UK. Matched normal tissue was taken in
parallel for each patient and samples were evaluated by a pathol-
ogist immediately following dissection. Informed consent was
obtained from each patient, and the study was conducted after
formal approval from local Hospital Ethics Committees. We did
not generate any primary tumor derived cell lines from the resected
material.
REAGENTS
TrichostatinA (TSA) was purchased from Calbiochem (San Diego,
CA, USA) and dissolved in DMSO. Cell cultures were treated for a
period of 24 h, at a final concentration of 250 ng/mL.
Suberoylanilide Hydroxamic Acid (SAHA) was obtained from
Cayman Chemical (Ann Arbor, MI, USA) and dissolved in DMSO.
Cell cultures were treated for 24 h, at a final concentration of
5µM).
5-Aza-2′-Deoxycytidine (DAC) was purchased from Merck
(Darmstadt, Germany) and dissolved in methanol. Cell cultures
were treated with DAC (final concentration – 0.2 or 1µM) for
48 h with DAC and media replaced every 24 h.
2′-Deoxy-2′,2′-difluorocytidine hydrochloride (Gemcitabine –
GEM) was supplied by Eli Lilly (Indianapolis, IN, USA) and dis-
solved in PBS at a final concentration of 38 mg/mL (120.14 mM).
Cell cultures were treated with GEM (final concentration – 0.2 or
1µM) for 48 h with GEM with media and drug replaced every 24 h.
Frontiers in Oncology | Thoracic Oncology June 2013 | Volume 3 | Article 162 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baird et al. Epigenetics underpinning IL-23R expression in NSCLC
Apilimod (STA 5326) was purchased from Axon Medichem
BV (Groningen, Netherlands). Cells were treated at various
concentrations ranging from 0.1µM to 1 mM for 72 h.
RNA ISOLATION AND RT-PCR AMPLIFICATION
Total RNA was extracted using TRI reagent ®(MRC, Cincinnati,
OH, USA) according to the manufacturer’s instructions. Prior to
first strand cDNA synthesis, 1µg of total RNA was pre-treated by
digestion with RQ1 DNase (Promega, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. cDNA was generated using
RevertAid (Fermentas, St. Leon-Rot, Germany) and OligodT(20)
primers according to the manufacturer’s instructions.
Cell lines were examined for the expression of IL-
23R (171 bp) (Forward 5′-CAGGTCACTATTCAATGGGATGC-
3′, Reverse 5′-GCAGTTCTTAATTGCTGCTTGG-3′) and Beta-
actin (510 bp) (Forward 5′-AGCACTGTGTTGGCGTACAG-3′,
Reverse 5′-TGTTTGAGACCTTCAACACCC-3′) by RT-PCR.
Cycling conditions consisted of: 95°C for 5 min followed by 35
cycles of 1 min at 94°C, 1 min at the target gene annealing temper-
ature (IL-23R – 58°C, Beta-actin – 55°C) and 1 min at 72°C with
a final extension at 72°C for 10 min.
To examine IL-23R expression in primary patient mater-
ial, we compared IL-23R mRNA levels in the tumor tissue to
matched normal tissue from the same individual as follows. The
samples were subjected to RT-PCR for IL-23R and Beta-Actin,
and electrophoresed on 2% agarose gels. If there was a distinct
(visible) change in expression samples were classified as either
up/down/unchanged.
Subsequently we conducted “semi-quantitative” densitometric
analysis on the gene expression. IL-23R expression was normalized
to the Beta-Actin loading control which resulted in a discrete ratio
value. The values for all samples were averaged and a Student’s
t-test was performed to compare Normal versus Tumor IL-23R
expression. No cut off points were used and all data is based on
the average values obtained.
Experiments conducted on cell lines were carried out in trip-
licate and PCR products electrophoresed on a 2% agarose gel.
Product quantification was performed using TINA 2.09c (Raytest,
Isotopenmeßgeräte GmbH, Straubenhardt, Germany) densitom-
etry software. The target mRNA expression was normalized to
Beta-actin controls, and was expressed as a ratio of target mRNA
expression: Beta-actin expression.
CHROMATIN IMMUNOPRECIPITATION
Chromatin immunoprecipitation (ChIP) was performed as fol-
lows: following treatments, cells were fixed with formaldehyde
(final concentration 1%), suspended in SDS lysis buffer (Millipore,
Billerica, MA, USA) and sonicated until DNA was fragmented into
lengths of between 200 and 1000 bp. Aliquots of this sheared DNA
were subsequently immunoprecipitated using the OneDayChIP
Kit ™(Diagenode, Liege, Belgium) according to the manufacturer’s
instructions.
The antibodies used for immunoprecipitation were as fol-
lows: pan acetyl-histone H3 (H3Ac) (Millipore, Cat#06-599),
pan acetyl-histone H4 (H4Ac) (Millipore, Cat#06-598), acetyl-
histone H3 Lys 9/14 (H3K9/14ac) (Diagenode, Cat#pAb-
ACHBHS-044), acetyl-histone H3 Lys 9 (H3K9Ac) (Diagenode,
Cat#pAb-ACHAHS-044), di methyl-histone H3 Lys 9 (H3K9Me2)
(Sigma, Cat#D5567), di methyl-histone H3 Lys 4 (H3K4Me2)
(Sigma, Cat#D5692), methyl-histone H3 Lys 4 (H3K4Me)
(Sigma, Cat#M4819), and acetyl-histone H3 Lys 9 phosphoSer10
(H3K9S10) (Sigma, Cat#H0788). A no antibody control was
included to test for non-specific binding.
Primers used to study the promoter region of IL-
23R by ChIP (172 bp) were designed from the pro-
moter sequence at the Transcriptional Regulatory Element
Database (http://rulai.cshl.edu/TRED) (Jiang et al., 2007),
(Forward 5′-TTCTGCCTCTTGGATGAGACC-3′, Reverse 5′-
CAGAGCCCTGACCTACATTGC-3′). PCR cycling conditions
consisted of: 95°C for 5 min followed by 35 cycles of 1 min at
94°C, 1 min at the 58°C, and 1 min at 72°C with a final extension
at 72°C for 10 min.
PROLIFERATION ASSAY
Cell proliferation was measured using a Cell Proliferation ELISA,
BrdU (Roche Diagnostics Ltd., Sussex, UK). Briefly, cells were
seeded at 53× 103/well in a 96-well plate and adhered overnight.
Subsequently the complete media was removed and the cells
washed with 100µL PBS. Serum depleted media (0.5% FBS)
was added, as this mimics more closely physiological conditions.
Inhibition studies were carried out by treating cells with various
concentrations of Apilimod (0.1µM–1 mM) for 72 h. Absorbance
was measured on a plate reader at 450 nm with a reference wave-
length set to 690 nm. Blank and untreated (UT) wells were used
for normalization purposes. The UT cells were set as 100%, and
the Apilimod treatments assessed relative to this.
STATISTICAL ANALYSIS
The data are expressed as mean± SEM. Statistical analysis was per-
formed with Graphpad Prism 5.01 (Graphpad Software, La Jolla,
CA, USA) using either Student’s t -test or a one-way analysis of
variance (ANOVA) where groups in the experiment were three
or more. Following ANOVA a post hoc test was performed using
Dunnett’s Multiple Comparison Test. Differences were considered
significant when p< 0.05.
RESULTS
IL-23R IS EXPRESSED IN PRIMARY NSCLC SPECIMENS
IL-23R expression was examined in a panel of normal/tumor
matched NSCLC patient samples using RT-PCR Representative
images are shown in Figure 1A. A summary of the results is
shown in Figure 1B. Overall, there was an increase observed in IL-
23R (23/37, 62%) in the tumor compared with normal. This did
not reach significance for either the overall or separated cohorts
of patient samples. Graphed densitometry analysis is shown in
Figure 1C.
IL-23R EXPRESSION IS EPIGENETICALLY REGULATED THROUGH
HISTONE ACETYLATION
Using the histone deacetylase inhibitor (HDi), Trichostatin A
(TSA), significant induction of IL-23R was observed in both the
A549 and SK-MES-1 cell lines (Figure 2A) (p< 0.05). This induc-
tion of IL-23R expression indicates that this gene is epigenetically
regulated at the level of histone acetylation. Confirmation of this
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FIGURE 1 | IL-23R mRNA expression in normal/tumor NSCLC matched
pairs. (A) Levels of IL-23R were examined by RT-PCR on a panel of 37
NSCLC [adenocarcinoma (n=21) and squamous cell carcinoma (n=16)]
patient samples. Representative images of up and down regulated samples
are shown. (B) A summary of the changes in expression of IL-23R in a panel
of tumor/normal matched patient NSCLC samples. (C) Overall densitometry
analyses of tumor/normal matched patient NSCLC samples. Beta-actin
levels were used for normalization purposes. Data is expressed as
mean±SEM (n=37). Statistical analysis was performed using a paired
one-tailed Student’s t -test (N, normal; T, tumor; Adeno, adenocarcinoma;
Squam, squamous cell carcinoma; Both – combined Adeno and Squam).
was obtained using treatment with the FDA approved HDi, SAHA
(Vorinostat), which also resulted in increased IL-23R expression
in both of the NSCLC cell lines examined (Figure 2B) (p< 0.05).
REGULATION OF IL-23R OCCURS THROUGH DIRECT CHROMATIN
REMODELING
A ChIP analysis of the IL-23R promoter from A549 cells pre-
treated with TSA was used to verify that the observed effects for
HDi were due to increased histone hyperacetylation. As shown in
Figure 3, clear enrichment of histone acetylation was observed at
the IL-23R promoter in response to TSA, indicated by an increase
in the amount of PCR product for acetylated Histone H3 and H4.
We show that lysine 9 and lysine 14 are also hyperacetylated in
the IL-23R promoter region. Additional evidence that IL-23R is
dynamically regulated by histone post-translational modifications
is observed by an increase in histone H3 lysine 4 di methylation
(H3K4me2) marker. The ChIP analysis confirms that chromatin
remodeling is directly involved with the induction of IL-23R gene
expression.
IL-23R IS ALSO REGULATED THROUGH DNA CpG METHYLATION
Expression of IL-23R was examined in the A549 cells post-
treatment with a DNA methyltransferase inhibitor (5-Aza-2′-
Deoxycytidine – DAC) for 48 h (Figure 4A). DAC treatment signif-
icantly increased the mRNA expression of IL-23R at both concen-
trations tested (0.2, 1µM, p< 0.05) in the A549 cells (Figure 4B).
These results would suggest that the partial methylation of CpG
islands in the IL-23R promoter is important in the regulation of
this gene.
GEMCITABINE TREATMENT RESULTS IN INCREASED EXPRESSION OF
IL-23R
Gemcitabine (GEMZAR ® – Eli Lilly and Company) in combina-
tion with cisplatin is FDA approved for the first-line treatment of
patients with NSCLC. A549 cells were treated with Gemcitabine
(Gray et al., 2012) for a period of 48 h with drug and media
replaced every 24 h. RT-PCR was utilized to determine changes in
IL-23R expression (Figure 5A). Similar to the results observed with
DAC, GEM treatment significantly increased the expression of
IL-23R at concentrations of 0.2 and 1µM (Figure 5B) (p< 0.05).
APILIMOD (STA 5326) DECREASES THE PROLIFERATIVE CAPACITY OF
NSCLC CELLS
We have previously shown that IL-23 is pro-proliferative in NSCLC
(Baird et al., 2013). The A549 and SK-MES-1 cell lines were
treated with various doses of Apilimod (0.1, 1, 10, 100µM, and
1 mM) for 72 h and proliferation measured using a Cell Prolifer-
ation ELISA (Figure 6). All five doses of compound significantly
reduced the proliferative capacity of both cell lines (Figure 6).
However, the A549 cell lines demonstrated increased sensitiv-
ity to Apilimod (Figure 6A) compared with the SK-MES-1 cell
line (Figure 6B). For instance even at the lowest concentration at
0.1µM the proliferative rate in the A549 cell line (compared with
UT) was reduced by almost 50% (53.94± 4.72%) in contrast to
the SK-MES cell line (compared with UT) which was reduced by
approximately 15% (85.6± 3.57%). At the highest concentration
examined (1 mM), proliferation reduced by 40% in the squamous
cell line (62.57± 1.25%), however in the adenocarcinoma cell line
the rate decreased by 80% (19.56± 2.63%). These marked differ-
ences between the cell lines most likely reflect the contrast observed
previously with recombinant IL-23 treatment (Baird et al., 2013),
which was confirmed by Ping Lin and colleagues (Li et al., 2013).
As such differential receptor expression may play a role in lung
cancer cellular response to Apilimod.
DISCUSSION
This study builds on previous work undertaken in our laboratory,
where we demonstrated increased expression of IL-23 in NSCLC
and the pro-proliferative effect of recombinant IL-23 treatment
(Baird et al., 2013). These results were independently confirmed
in a separate study carried out by Li et al. (2013). We were the
first to establish that IL-23 was subject to epigenetic regulation
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FIGURE 2 | Histone deacetylase inhibitors (HDi) induce IL-23R
expression in NSCLC cell lines. (A)Treatment with TSA (250 ng/mL)
induced the expression of IL-23R in the A549 and SK-MES-1 cell lines.
(B) Induction of IL-23R was also observed in both cell lines with SAHA
treatment (5µM). Densitometry analysis of expression in treated
versus untreated samples when normalized to Beta-actin. Data is
graphed as mean±SEM (n=3). Statistical analysis was performed
using an unpaired Student’s t -test (*p<0.05; **p<0.01;
***p< 0.001) (UT, untreated; TSA, Trichostatin A; SAHA, Suberoylanilide
Hydroxamic Acid).
in NSCLC. We therefore wished to examine the IL-23/IL-23R axis
in further detail in NSCLC given the involvement of this path-
way in airway inflammation, and its potential therapeutic utility
(Miossec and Kolls, 2012).
The expression of the IL-23R was determined in a panel of
37 NSCLC normal tumor matched patient tissues. Although an
overall increase in expression was observed in tumor compared
with normal (Figure 1B), this did not reach significance in the
overall cohort or when the cohorts where stratified into specific
NSCLC subtypes (Figure 1C). These results however, reflect what
was observed previously in other studies involving lung cancer
(Zhang et al., 2006; Li et al., 2013). We did not however, examine
the mutational status of our patient cohort. As IL-23 can mediate
STAT3 and PI3K signaling pathways amongst others, it is per-
haps possible that constitutive activated pathways seen in NSCLC
patients harboring these mutations, may be at increased risk of
several cross talk feedback mechanisms, further perpetuating an
oncogene addiction state. This may result in increased levels of
IL-23R. To our knowledge at present there is no existing data in
the literature which has determined whether NSCLC mutational
status alters or affects the IL-23/IL-23R axis.
IL-23R levels were significantly induced (p< 0.05) following
HDi treatment in the both an adenocarcinoma (A549) and a
squamous cell carcinoma (SK-MES-1) cell line (Figure 2). Using
ChIP, we confirmed that HDi acts by directly remodeling the IL-
23R promoter region (Figure 3). As is demonstrated in Figure 3,
HDi treatment results in increased acetylation on histones H3 and
H4 at the IL-23A promoter, along with other post-translational
modifications associated with either transcriptionally active chro-
matin or at poised promoters (Berger, 2007; Pekowska et al., 2010).
HDACs and Lysine demethylases (KDMs) are both linked with
the regulation of gene transcription, and HDi can inhibit lysine
demethylases causing increased H3K4me2 (Lee et al., 2006; Huang
et al., 2011), in agreement with the results observed by us at the
IL-23R promoter (Figure 3).
Treatment of the A549 cell line with a DNMTi (DAC) resulted in
a significant up-regulation of IL-23R (p< 0.05, Figure 4), indicat-
ing that in addition to histone post-translational modifications,
DNA CpG methylation at the promoter region is also involved
in the regulation of this gene. Treatment with the chemothera-
peutic agent, Gemcitabine, also induced the expression of IL-23R
(p< 0.05, Figure 5). We have previously shown that Gemcitabine
is a potential DNMTi (Gray et al., 2012).
Finally, we treated NSCLC cells with a small molecule capa-
ble of inhibiting IL-12/IL-23 production. Cells were treated with
Apilimod for a period of 72 h, after which time the proliferative
capacity of the cells was determined (Figure 6). The adenocarci-
noma cell line (A549) displayed enhanced sensitivity to the com-
pound compared to the SK-MES-1 cell line, although apilimod
caused significant decreases in both cell lines overall (Figure 6).
An approximate 50% reduction in A549 proliferation was evident
at 0.1µM, however a 50% decrease was not reached in the SK-
MES-1 cell line even at the highest dose of 1 mM. These differential
responses may in part be due to differential receptor expression, as
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FIGURE 3 | Histone acetylation occurs directly at the promoter region
of IL-23R.The ChIP assay demonstrates that TSA treatment results in an
increase in the acetylation of histone H3 and H4. A549 cells were cultured
in the presence or absence of TSA (250 ng/mL) for a period of 24 h.
Subsequently, a ChIP assay was performed using the following antibodies;
pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone
H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone
H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di
methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9
(H3K9Me2). Input DNA serves as a positive control as recommended by
the manufacturer (Diagenode). A no antibody control was included to test
for non-specific binding (UT, untreated; TSA, Trichostatin A).
both cell lines robustly express IL-12Rβ1, however IL-23R is only
expressed in the A549 cell line (Baird et al., 2013). We and oth-
ers have shown that IL-23R levels can affect a cell line’s response
to IL-23 (Baird et al., 2013; Li et al., 2013; Shen et al., 2013) and
this would appear to translate to differential responses to Apil-
imod. Various splice isoforms of IL-23R have also been identified
and differ between NSCLC subtypes, which may also affect the
response to Apilimod (Zhang et al., 2006). It may however be pos-
sible to use IL-23R expression as a candidate biomarker to predict
responsiveness to Apilimod therapy.
The IC50 values for the lung cell lines are of a much higher
magnitude than that seen for PBMC, where an IC50 of 10 nM
was observed (Wada et al., 2007), and may possibly be due to the
aggressive nature of lung cancer cells. Nevertheless, a recent Phase
2a multi-center, open-label clinical trial has completed in pso-
riasis patients with the predominant focus on biomarker-based
measures of biological response (Wada et al., 2012). In this study
patients received doses of Apilimod up to 70 mg once daily. The
maximum Apilimod concentration observed in plasma at this dose
was 265± 183 nM 2 h post-dose (Wada et al., 2012). It would
appear that 70 mg (twice daily) is the maximum dose tolerable
as CNS-related adverse events (headache, flushing, hypoesthesia,
dizziness, and paresthesia) were observed at a 105 mg BID dose
FIGURE 4 | Cell line response to a DNA methyltransferase inhibitor
(DNMTi). (A)The effect of 5-aza-2′deoxycytidine (DAC) treatment on the
expression of IL-23R. A549 cells were cultured in either 0.2 or 1.0µM DAC
for 48 h with media and drug replaced every 24 h. A PCR was also carried
out for Beta-actin to determine loading efficiency and for normalization
purposes. (B) Densitometry analysis of expression in treated versus
untreated samples when normalized to Beta-actin. Data is graphed as
mean±SEM (n=3). Statistical analysis was performed using an unpaired
Student’s t -test (*p<0.05) (UT, untreated; DAC, 5-aza-2′deoxycytidine).
level in a Phase I study (Wada et al., 2012). As we observe a sig-
nificant decrease in cellular proliferation in our NSCLC cell lines
at concentrations as low as 100 nM, particularly for those cells
that express significant levels of IL-23R (A549), potential clinical
efficacy may be achieved using this dose.
Based on our results, IL-23R is expressed in a set of primary
NSCLC tumors. The expression of IL-23R in NSCLC was found
to be dynamically regulated both by chemotherapy drugs and
epigenetic mechanisms. These results may, therefore, have impor-
tant implications for treating patients with epigenetic targeting
therapies and/or Gemcitabine. Our results indicate that HDAC
inhibitors may not be a viable therapeutic treatment option in
NSCLC, at least as a single entity given that in our experience, both
SAHA and TSA increase the expression of both IL-23 and IL-23R
levels. Combinational studies would be warranted to determine
if HDACi therapy would be more valuable in combination with
Apilimod.
The results presented here may have implications for the dif-
ferential treatment of adenocarcinoma and squamous cell carci-
noma NSCLC patients. Although Gemcitabine is usually given
in a combination therapy with cisplatin for squamous cell carci-
noma patients, our study has shown that Gemcitabine increases
the levels of IL-23R in both NSCLC subtypes. Therefore should
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the IL-23 axis prove to be a prognostic marker in NSCLC, Gem-
citabine may not be therapeutically advantageous for squamous
cell carcinoma patients. Apilimod may however be a beneficial
FIGURE 5 |Treatment with the chemotherapy drug, Gemcitabine,
induces the expression of IL-23R . (A)The effect of Gemcitabine treatment
on the expression of IL-23R. A549 cells were cultured in either 0.2 or 1.0µM
Gemcitabine for 48 h with media and drug replaced every 24 h. A PCR was
also carried out for Beta-actin to determine loading efficiency and for
normalization purposes. (B) Densitometry analysis of expression in treated
versus untreated samples when normalized to Beta-actin. Data is graphed
as mean±SEM (n=3). Statistical analysis was performed using an
unpaired Student’s t -test (*p<0.05) (UT, untreated; GEM, gemcitabine).
treatment option for NSCLC patients that express a functional
IL-23R, given that it results in significant decreases in prolifera-
tion in the A549 adenocarcinoma cell line which expresses higher
levels of the IL-23R than the SK-MES-1 cell line. It is possible
that IL-23R levels may represent a novel potential biomarker for
sensitivity to Apilimod. We have not examined the expression lev-
els in additional adenocarcinoma and squamous cell carcinoma
NSCLC cell lines. However, in the paper by Lin and colleagues (Li
et al., 2013) IL-23R receptor expression levels in A549 and SK-
MES, were similar to our observations, confirming our data. They
also examined levels IL-23R receptor levels in a large cohort of
patient samples (n= 137). According to their data, IL-23R pos-
itivity was observed in 85–90% of adenocarcinomas and small
cell carcinomas, while IL-23R positivity was only observed in
7.5% of squamous cell carcinomas (Li et al., 2013 supplementary
Table 2).
There also exists the possibility that combinatorial treatments
with Apilimod and standard chemotherapies may have addi-
tive or synergistic effects. To our knowledge, there is currently
no data available examining the effect of cisplatin or other
platinum agents on IL-23R expression in lung cancer. How-
ever as platinum based agents have been shown to increase
the expression of a number of inflammatory mediators such
as NF-kB, it is therefore conceivable that cisplatin based ther-
apy may increase the expression of IL-23/IL-23R. Currently we
are examining IL-23 and IL-23R expression levels in a panel
of isogenic of parent (sensitive) and resistant NSCLC cell lines
generated in our unit (Barr et al., 2013) with a view to conduct-
ing combination treatments of Apilimod and cisplatin in future
studies.
Further study is needed to elucidate the clinical impact of
targeting the IL-23/IL-23R axis in NSCLC. A larger IHC study
will be required to fully correlate expression levels with clinico-
pathological data and to determine if IL-23R levels can act as a
biomarker for sensitivity to anti-IL-23 mediated therapies.
Finally, to our knowledge, this is the first study to examine the
potential utility of Apilimod in a cancer setting where we have
FIGURE 6 | Decreases in NSCLC cellular proliferation are observed
post-Apilimod (STA 5326) treatment. Cell proliferation was examined by a
Cell Proliferation ELISA following 72 h of stimulation with Apilimod
(0.1µM–1 mM) in the (A) A549 and (B) SK-MES-1 cell lines. All treatment
doses resulted in marked decreased proliferation in the A549 cells when
compared with the SK-MES-1 cells. Data is represented as a percentage of
the untreated control (UT), which was set to 100% and is expressed as
mean±SEM (n=3). Statistical analysis was performed using a One-way
ANOVA and a post hoc Dunnett’s Multiple Comparison Test (***p<0.001;
**p<0.01).
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shown that this compound can significantly reduce the prolifera-
tive rate of NSCLC cells. It has recently been shown that levels of
IL-23 are elevated in breast cancer (Qian et al., 2013b). Although
currently in clinical trials for auto-immune conditions, it may be
therefore be worthwhile to further examine the efficacy of this
compound in the treatment of lung cancer and other cancers.
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